Dishman Carbogen Amcis Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
DCAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 12.4 pts more than Nifty Microcap 250 and 12.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dishman Carbogen Amcis reported strong consolidated FY2026 results with total income of Rs 2,931.90 Crores (up 8.1% from Rs 2,711.50 Crores) and net profit of Rs 97.45 Crores, a massive jump from Rs 3.24 Crores in FY2025. However, standalone results show a concerning picture with income declining to Rs 231.56 Crores from Rs 399.84 Crores and a net loss of Rs 38.40 Crores (vs loss of Rs 9.87 Crores). The company also disclosed taking an ECB of up to CHF 200 million (approx Rs 2,452 Crores) from promoter entity Aamanya AG to refinance existing debt. Auditors issued an unmodified opinion but included Emphasis of Matter on goodwill accounting treatment (changed amortization life from 15 to 99 years) and a standalone financial covenant deviation on Rs 84.44 Crores of debentures (waivers obtained from debenture holders).
The consolidated results show strong profitability growth and margin expansion, but the large standalone losses and covenant deviation at standalone level raise concerns. The large ECB from promoter group (related party transaction) increases debt levels and will require close monitoring.